Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nateglinide · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Nateglinide | EXPERIMENTAL | Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited |
| Starlix | ACTIVE_COMPARATOR | Starlix Tablets 120 mg of Novartis |
| Name | Type | Description |
|---|---|---|
| Nateglinide | DRUG | Nateglinide Tablets 120 mg |
Inclusion Criteria: * Male or female, smoker or non-smoker, 18 years of age and older. * Capable of consent Exclusion Criteria: Subjects to whom any of the following applies will be excluded from the study: * Clinically significant illnesses within 4 weeks prior to the administration of the stud...
Nateglinide is a small molecule drug developed by Dr. Reddy's Laboratories Ltd. It is being studied in Phase 1 clinical development. The specific medical conditions it is intended to treat have not been disclosed. It is not described as an approved product in the available development information.
Nateglinide targets KCNJ11 and ABCC8. It acts as a blocker of these targets. KCNJ11 and ABCC8 are components of ATP-sensitive potassium channels. By blocking these channels, the drug is designed to influence channel activity, which is the basis of its pharmacological action.
Nateglinide is developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. The company is responsible for the clinical development of this small molecule drug candidate.
Nateglinide is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no active trials are currently listed. The drug is investigational and has not been approved for any indication based on the available development information.
Nateglinide has been evaluated in two completed Phase 1 trials: NCT01160029, a bioequivalence study under fed conditions with 58 healthy volunteers, and NCT01159158, a bioequivalence study under fasting conditions with 68 healthy volunteers. Both trials were active-controlled and randomized, with a total enrollment of 126 participants.